Rocket Pharmaceuticals, Inc. (RCKT)

Market Cap	312.44M
Revenue (ttm)	n/a
Net Income (ttm)	-258.03M
Shares Out	107.74M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,748,943
Open	2.910
Previous Close	2.880
Day's Range	2.845 - 2.960
52-Week Range	2.190 - 26.980
Beta	0.68
Analysts	Buy
Price Target	18.50 (+537.93%)
Earnings Date	Aug 4, 2025

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 299
• Stock Exchange: NASDAQ
• Ticker Symbol: RCKT
• Website: https://www.rocketpharma.com

Analyst Summary

According to 13 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 537.93% from the latest price.

Price Target

$18.5

(537.93% upside)

Analyst Consensus: Buy